Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28587997 | 0.82 | SMN1; SMN2 (0.68) | KMT2AGAAHDAC1HDAC2HDAC3 | |
| SCHEMBL25845880 | 0.81 | HDAC3 (0.60) | KMT2AGAAHDAC1HDAC2HDAC3 | |
| SCHEMBL12791628 | 0.79 | CETP (0.64) | KMT2AGAAHDAC1HDAC2HDAC3 | |
| SCHEMBL27884370 | 0.76 | CYP1A2 (0.55) | KMT2AGAAHDAC1HDAC2HDAC3 | |
| SCHEMBL678484 | 0.73 | PTPN1 (0.74) | KMT2AGAAHDAC1HDAC2HDAC3 | |
| SCHEMBL24730776 | 0.73 | KMT2A (0.51) | KMT2AHDAC1HDAC2SMN1; SMN2MEN1 | |
| SCHEMBL4218895 | 0.73 | ALDH1A1 (0.68) | HDAC1HDAC2HDAC3SMN1; SMN2LMNA | |
| SCHEMBL29948499 | 0.73 | KMT2A (0.51) | KMT2AHDAC1HDAC2SMN1; SMN2MEN1 | |
| SCHEMBL26122265 | 0.73 | KMT2A (0.59) | KMT2AGAAHDAC1HDAC2HDAC3 | |
| SCHEMBL20332958 | 0.73 | ALDH1A1 (0.68) | HDAC1HDAC2HDAC3SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | KMT2A 289/4885GAA 4316/4885HDAC1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.